Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

Short DAPT All That’s Needed With Contemporary DES: HOST-IDEA at 3 Years

News Conference News EuroPCR 2025

Short DAPT All That’s Needed With Contemporary DES: HOST-IDEA at 3 Years

Yael L. Maxwell

June 02, 2025

Short DAPT Safe in ACS With No Ischemic Penalty: 4D-ACS

News Conference News EuroPCR 2025

Short DAPT Safe in ACS With No Ischemic Penalty: 4D-ACS

May 30, 2025

Short DAPT in High-Bleeding-Risk Patients Reduces Recurrent Events: MASTER DAPT

News Conference News EuroPCR 2025

Short DAPT in High-Bleeding-Risk Patients Reduces Recurrent Events: MASTER DAPT

Yael L. Maxwell

May 23, 2025

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

News Conference News EuroPCR 2025

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

Michael O'Riordan

May 20, 2025

One-month DAPT followed by 5-month Ti - cagrelor monotherapy in acute coronary syndromes with DCB - results from REC-CAGEFREE II

Presentation EuroPCR 2024

One-month DAPT followed by 5-month Ti - cagrelor monotherapy in acute coronary syndromes with DCB - results from REC-CAGEFREE II

Presenter: Ling Tao

May 15, 2024

Stepwise DAPT De-escalation Shows Promise in DCB-Only PCI for ACS

News Conference News EuroPCR 2024

Stepwise DAPT De-escalation Shows Promise in DCB-Only PCI for ACS

Yael L. Maxwell

May 15, 2024

Methodological Insight: REC-CAGEFREE II Trial

Presentation EuroPCR 2024

Methodological Insight: REC-CAGEFREE II Trial

Presenter: Robert Byrne

May 14, 2024

‘Fascinating’ Unlocking Coronary Stent Prompts Cautious Praise

News Conference News EuroPCR 2023

‘Fascinating’ Unlocking Coronary Stent Prompts Cautious Praise

Michael O'Riordan

May 18, 2023

Long-term Outcomes With PCI and CABG: More Analyses to Stir the Pot

News Conference News EuroPCR 2022

Long-term Outcomes With PCI and CABG: More Analyses to Stir the Pot

Michael O'Riordan

May 23, 2022

Subcutaneous GP IIb/IIIa Inhibitor in STEMI Is Fast, Potent in Early Study

News Conference News EuroPCR 2021

Subcutaneous GP IIb/IIIa Inhibitor in STEMI Is Fast, Potent in Early Study

May 18, 2021

Tirofiban Provides Better Platelet Inhibition Than Cangrelor in STEMI Patients

News Conference News EuroPCR 2020

Tirofiban Provides Better Platelet Inhibition Than Cangrelor in STEMI Patients

Michael O'Riordan

June 30, 2020

No Survival Benefit With Revascularization in Stable CAD, Meta-analysis Confirms

News Conference News EuroPCR 2020

No Survival Benefit With Revascularization in Stable CAD, Meta-analysis Confirms

Michael O'Riordan

June 26, 2020

Daring to Dream: New BRS Data Hint at Low MACE Rates at 2 and 3 Years

News Conference News EuroPCR 2019

Daring to Dream: New BRS Data Hint at Low MACE Rates at 2 and 3 Years

Michael O'Riordan

May 27, 2019

Long-term Ticagrelor Monotherapy May Have an Edge in Complex PCI Patients: GLOBAL LEADERS

News Conference News EuroPCR 2019

Long-term Ticagrelor Monotherapy May Have an Edge in Complex PCI Patients: GLOBAL LEADERS

Michael O'Riordan

May 21, 2019

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

News Conference News EuroPCR 2019

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

May 16, 2019

ORBITA Deep Dive Highlights Treatment Choices, Social Media, and Ethics

News Conference News EuroPCR 2018

ORBITA Deep Dive Highlights Treatment Choices, Social Media, and Ethics

Michael O'Riordan

May 31, 2018

“Transient” STEMI Patients Can Be Immediately Treated or Safely Deferred to Next Day

News Conference News EuroPCR 2018

‘Transient’ STEMI Patients Can Be Immediately Treated or Safely Deferred to Next Day

Michael O'Riordan

May 24, 2018

Modest Benefit of PCI Over Medical Therapy in Patients With ‘Grey Zone’ FFR Lesions

News Conference News EuroPCR 2018

Modest Benefit of PCI Over Medical Therapy in Patients With ‘Grey Zone’ FFR Lesions

Michael O'Riordan

May 23, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.